H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on Roivant Sciences (ROIV) to $23 from $20 and keeps a Buy rating on the shares. The company postponed topline data from two Phase 3 trials of batoclimab to 1H26 from 2H25, which management attributed to competitive reasons, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ROIV:
- Roivant Sciences price target raised to $25 from $21 at Guggenheim
- Roivant Sciences Reports Q2 2025 Financial Results
- Roivant Sciences price target raised to $26 from $25 at Citi
- Promising Developments and Strong Financial Position Justify Buy Rating for Roivant Sciences
- Roivant Sciences reports Q2 EPS (17c), consensus (30c)